Emiliano Navarra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emiliano Navarra has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Philippe Noirhomme
Department of Cardiovascular and Thoracic Surgery, Saint-Luc Hospital, Catholic University of Louvain, Brussels, Belgium
2 shared publicationsChristine Watremez
1 shared publicationGaby Aphram
Department of Cardiovascular and Thoracic Surgery, Saint-Luc Hospital, Catholic University of Louvain, Brussels, Belgium
1 shared publicationGebrine El Khoury
Department of Cardiovascular and Thoracic Surgery, Saint-Luc Hospital, Catholic University of Louvain, Brussels, Belgium
1 shared publication- Gebrine El Khoury
Department of Cardiovascular & Thoracic Surgery, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCL), Brussels, Belgium
1 shared publication Giovanni Melina
Cardiac Surgery Unit, Ospedale Sant'Andrea, "Sapienza" University of Rome, Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 1 November 2022
- Published by AME Publishing Company in Annals of Cardiothoracic Surgery
- Vol. 11 (6) , 589-595
Robotic mitral valve repair—the Bruxelles experience
Background: Although the use of the surgical robot facilitates less invasive mitral valve surgery, both real and perceived limitations have slowed the application of this technology. Aim of the present investigation was to report the early and long-term results of robotic mitral valve repair in a single institution over a 10 years period. Methods: Between March 2012 and May 2022, a total of 278 consecutive patients underwent robotically assisted mitral valve repair at the Cliniques Universitaires Saint-Luc (Brussels, Belgium). Indications have evolved over time allowing to treat complex mitral valve lesions. Clinical and echocardiographic follow-up were 97.8% and 86.1% complete, respectively. Results: Mean age of the study population was 57.8±11.9 years and 221/278 (79.5%) patients were male. Despite being asymptomatic or mildly symptomatic [New York Heart Association (NYHA) class I–II], most of the patients presented with severe mitral regurgitation (MR). Degenerative mitral valve disease was the most common cause of MR. All patients underwent successful mitral valve repair using different techniques, and 25/278 (9.0%) had one or more concomitant procedures associated. The mean cardio-pulmonary bypass and aortic cross clamp times were 153±37 and 106±25 minutes, respectively. There was no operative or in-hospital mortality. Overall survival rate was 97.8%±3.2%, 95.8%±3.2% and 93.7%±3.0% at 3, 7 and 10 years. One early (0.4%) reoperation with re-repair was recorded for ring disruption, while late mitral valve re-repair was necessary in 4/279 (1.4%) patients for recurrent severe MR in three of them and mitral endocarditis in one. The overall freedom from mitral valve reoperation was 98.1%±1.0% at 3, 7 and 10 years. Overall freedom from MR (grade 2+ or more) was 91.7%±3.2%, 77.8%±4.8% and 67.1%±9.2% at 3, 7 and 10 years, respectively. Conclusions: Robotic mitral valve repair is safe and is associated with excellent clinical and echocardiographic results. The use of robotic technologies allows, after an appropriate learning curve, to reproduce all conventional techniques to treat MR, regardless the complexity of the valve lesion.
- 1 November 2022
- Published by AME Publishing Company in Annals of Cardiothoracic Surgery
- Vol. 11 (6) , 589-595
Open AccessRobotic mitral valve repair—the Bruxelles experience
Background: Although the use of the surgical robot facilitates less invasive mitral valve surgery, both real and perceived limitations have slowed the application of this technology. Aim of the present investigation was to report the early and long-term results of robotic mitral valve repair in a single institution over a 10 years period. Methods: Between March 2012 and May 2022, a total of 278 consecutive patients underwent robotically assisted mitral valve repair at the Cliniques Universitaires Saint-Luc (Brussels, Belgium). Indications have evolved over time allowing to treat complex mitral valve lesions. Clinical and echocardiographic follow-up were 97.8% and 86.1% complete, respectively. Results: Mean age of the study population was 57.8±11.9 years and 221/278 (79.5%) patients were male. Despite being asymptomatic or mildly symptomatic [New York Heart Association (NYHA) class I–II], most of the patients presented with severe mitral regurgitation (MR). Degenerative mitral valve disease was the most common cause of MR. All patients underwent successful mitral valve repair using different techniques, and 25/278 (9.0%) had one or more concomitant procedures associated. The mean cardio-pulmonary bypass and aortic cross clamp times were 153±37 and 106±25 minutes, respectively. There was no operative or in-hospital mortality. Overall survival rate was 97.8%±3.2%, 95.8%±3.2% and 93.7%±3.0% at 3, 7 and 10 years. One early (0.4%) reoperation with re-repair was recorded for ring disruption, while late mitral valve re-repair was necessary in 4/279 (1.4%) patients for recurrent severe MR in three of them and mitral endocarditis in one. The overall freedom from mitral valve reoperation was 98.1%±1.0% at 3, 7 and 10 years. Overall freedom from MR (grade 2+ or more) was 91.7%±3.2%, 77.8%±4.8% and 67.1%±9.2% at 3, 7 and 10 years, respectively. Conclusions: Robotic mitral valve repair is safe and is associated with excellent clinical and echocardiographic results. The use of robotic technologies allows, after an appropriate learning curve, to reproduce all conventional techniques to treat MR, regardless the complexity of the valve lesion.
- 1 August 2016
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 25 (8) , e108
Robotic Mitral Repair: The ring issue
- 1 August 2016
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 25 (8) , e108
Robotic Mitral Repair: The ring issue